Drug Profile
Firuglipel - Daiichi Sankyo Company
Alternative Names: DS-8500; DS-8500aLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antihyperglycaemics; Benzamides; Cyclopropanes; Fluorobenzenes; Oxadiazoles; Phenyl ethers; Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in Canada (PO) (Daiichi Sankyo Company pipeline, September 2021)
- 11 Sep 2017 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
- 01 May 2017 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO) due to unfavourable study results (Daiichi Sankyo pipeline, May 2017)